Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Tsubota Laboratory Incorporated

Market Cap 758.35Cr 4.73Cr 4.07Cr 3.75Cr 3.52Cr 6.61Cr 446.86Cr 6.68Cr 44Cr 17Cr 218.83Cr 18Cr 17Cr P/E Ratio 2024
-14.1x
P/E Ratio 2025 49.7x
Enterprise Value 613.55Cr 3.82Cr 3.3Cr 3.03Cr 2.85Cr 5.35Cr 361.53Cr 5.41Cr 36Cr 14Cr 177.04Cr 14Cr 14Cr EV / Sales 2024
10.8x
EV / Sales 2025 6.38x
Free-Float
27.85%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.59Cr
-0.12%+1.04%-13.08%-12.43% 4.36TCr
-2.17%+4.70%+293.71%+535.99% 3.4TCr
+0.44%-2.46%+14.20%-17.35% 2.98TCr
-1.60%-1.58%-0.19%+31.82% 2.98TCr
-0.29%+9.47%+13.95%+21.93% 2.54TCr
+3.54%+8.43% - - 1.39TCr
-1.26%-1.11%+53.37%+108.10% 1.34TCr
-1.04%-3.33%+3.98%+3.91% 1.29TCr
-1.18%-2.00%+107.41%+78.18% 1.22TCr
Average -0.33%+2.03%+59.17%+93.77% 2.39TCr
Weighted average by Cap. -0.49%+2.02%+61.04%+105.13%

Financials

2024 2025
Net sales 67Cr 41.94L 36.15L 33.29L 31.25L 58.68L 40Cr 59.3L 3.93Cr 1.53Cr 19Cr 1.57Cr 1.54Cr 135.7Cr 84.57L 72.89L 67.12L 63.02L 1.18Cr 80Cr 1.2Cr 7.93Cr 3.09Cr 39Cr 3.17Cr 3.11Cr
Net income -64Cr -39.95L -34.43L -31.7L -29.77L -55.89L -38Cr -56.48L -3.75Cr -1.46Cr -18Cr -1.5Cr -1.47Cr 20Cr 12.78L 11.01L 10.14L 10L 17.87L 12Cr 18.06L 1.2Cr 46.68L 5.92Cr 47.95L 46.93L
Net Debt -176.7Cr -1.1Cr -94.91L -87.39L -82.06L -1.54Cr -104.12Cr -1.56Cr -10Cr -4.02Cr -51Cr -4.13Cr -4.05Cr -144.8Cr -90.25L -77.77L -71.62L -67.24L -1.26Cr -85Cr -1.28Cr -8.46Cr -3.3Cr -42Cr -3.39Cr -3.31Cr
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!